Skip to content
CompoundSci
All peptides
Research vial labelled Tesamorelin + Ipamorelin, a Growth hormone secretagogue peptide studied in preclinical and clinical literature

Tesamorelin + Ipamorelin

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

A GHRH analog paired with a selective secretagogue. Blends make it impossible to attribute any effect or side effect to one component.

General profile

Class
Growth hormone secretagogue
Evidence
Mixed or moderate evidence
Studied dose range
1 mg + 0.2 mg (blend labelling varies)
Frequency in protocols
Nightly, fasted
Route
Subcutaneous
Half life
Mixed, both short
Reconstitution
2 mL bacteriostatic water per blended vial
Storage
Refrigerated, ~28 days

Timing and cycling in the literature

Usually dosed in the bedtime window, fasted

Nightly, fasted

Both halves of the blend target the nocturnal growth-hormone pulse and both are blunted by recent food.

Reported cycle: 12 weeks on, 4 weeks off

Blend protocols follow the tesamorelin trial arc, where visceral fat changes were measured at twelve and twenty-six weeks.

Watch for: Glucose, joint swelling, and the fact that you cannot attribute anything to one half of a blend.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Separate syringesSame day fine, same syringe not

    Tesamorelin + Ipamorelin + BPC-157

    That GH pair can share a barrel, BPC-157 stays out

    Tesamorelin and ipamorelin sit in the same GH class and are co-drawn in practice. Adding a healing peptide to that barrel is a cross-family mix with no stability file.

  • Pick oneRedundant, pick one

    Tesamorelin + Ipamorelin + Ipamorelin

    Same target hit twice

    The blend already contains ipamorelin.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Tesamorelin + Ipamorelin fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature